Last Updated : April 25, 2012
Details
FilesGeneric Name:
Ranibizumab injection
Project Status:
Complete
Therapeutic Area:
Macular edema, secondary to retinal vein occlusion
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Lucentis
Project Line:
Reimbursement Review
Project Number:
SR0276-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Submission Type:
Initial
Indications:
Macular edema, secondary to retinal vein occlusion
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:
Files
Last Updated : April 25, 2012